James L Mohler

List of Publications by Year
in descending order

162 papers	7,889 citations	76196 40 h-index	56606 83 g-index
167 all docs	167 docs citations	167 times ranked	9400 citing authors

#	Article	IF	Citations
1	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
2	The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research, 2004, 10, 440-448.	3.2	629
3	Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4653-4657.	3.2	457
4	Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells. Molecular Endocrinology, 1997, 11, 450-459.	3.7	306
5	NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 620-623.	2.3	236
6	The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases. Advances in Urology, 2012, 2012, 1-18.	0.6	225
7	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8438-8443.	3.3	223
8	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	2.3	208
9	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European Urology, 2015, 67, 53-60.	0.9	205
10	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. Cancer Research, 2005, 65, 10514-10523.	0.4	186
11	Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. European Urology, 2017, 71, 183-192.	0.9	171
12	Steroid 5Î±-Reductase Isozymes I and II in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4365-4371.	3.2	166
13	Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer. Cancer Research, 2011, 71, 1486-1496.	0.4	135
14	Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer. Journal of Urology, 2003, 170, 1817-1821.	0.2	131
15	Racial Differences in Androgen Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. Journal of Urology, 2003, 170, 990-993.	0.2	129
16	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate, 2006, 66, 1292-1301.	1.2	129
17	Breast Cancer Resistance Proteinâ€“Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem Cells. Cancer Research, 2005, 65, 6640-6650.	0.4	119
18	Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP. Molecular Cancer Research, 2009, 7, 523-535.	1.5	112

#	Article	IF	Citations
19	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	5.8	96
20	5Î±â€reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate, 2011, 71, 1033-1046.	1.2	93
21	Castration-Recurrent Prostate Cancer Is Not Androgen-Independent. Advances in Experimental Medicine and Biology, 2008, 617, 223-234.	0.8	90
22	In vitro high resolution1h-spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magnetic Resonance in Medicine, 1993, 29, 285-291.	1.9	79
23	Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation. Cancer Research, 2007, 67, 9294-9303.	0.4	78
24	Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells. Cancer Research, 2006, 66, 5121-5129.	0.4	73
25	Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft. American Journal of Pathology, 2002, 160, 219-226.	1.9	70
26	Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone. Clinical Cancer Research, 2011, 17, 5844-5849.	3.2	65
27	Immunohistochemistry of the Androgen Receptor in Human Benign and Malignant Prostate Tissue. Journal of Urology, 1993, 149, 1015-1019.	0.2	64
28	Lipid degradation promotes prostate cancer cell survival. Oncotarget, 2017, 8, 38264-38275.	0.8	64
29	The North Carolinaâ€“Louisiana Prostate Cancer Project (PCaP): Methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate, 2006, 66, 1162-1176.	1.2	63
30	Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 2002, 51, 247-255.	1.2	62
31	Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft*. Endocrinology, 1999, 140, 2372-2381.	1.4	57
32	Expression of Annexin I, II and VII Proteins in Androgen Stimulated and Recurrent Prostate Cancer. Journal of Urology, 2004, 171, 916-920.	0.2	56
33	Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy. Journal of Urology, 2009, 181, 621-626.	0.2	54
34	Collagen Cross-Link Metabolites in Urine as Markers of Bone Metastases in Prostatic Carcinoma. Journal of Urology, 1994, 151, 909-913.	0.2	53
35	RACIAL DIFFERENCES IN PROSTATE ANDROGEN LEVELS IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 171, 2277-2280.	0.2	49
36	Surgical Competency for Urethrovesical Anastomosis During Robot-assisted Radical Prostatectomy: Development and Validation of the Robotic Anastomosis Competency Evaluation. Urology, 2015, 85, 27-32.	0.5	49

#	Article	IF	Citations
37	Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 1992, 69, 511-519.	2.0	47
38	Overexpression of cyclin D1 is rare in human prostate carcinoma. , 1999, 38, 40-45.		46
39	Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. Journal of Urology, 2017, 197, 1237-1244.	0.2	46
40	Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular Signalling, 2010, 22, 1554-1561.	1.7	44
41	Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E263-E275.	1.8	44
42	High intratumoral CD8⁺ Tâ€cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate, 2021, 81, 20-28.	1.2	43
43	Role of 5Î±-Reductase Inhibitors in Prostate Cancer Prevention and Treatment. Urology, 2012, 79, 1197-1205.	0.5	40
44	Associations between patientâ€“provider communication and socio-cultural factors in prostate cancer patients: A cross-sectional evaluation of racial differences. Patient Education and Counseling, 2014, 97, 339-346.	1.0	39
45	A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 357-372.	2.2	36
46	5Î±â€reductase type 3 enzyme in benign and malignant prostate. Prostate, 2014, 74, 235-249.	1.2	36
47	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 140.	3.8	36
48	Melanoma Antigen-A11 (MAGE-A11) Enhances Transcriptional Activity by Linking Androgen Receptor Dimers. Journal of Biological Chemistry, 2013, 288, 1939-1952.	1.6	33
49	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research, 2014, 20, 6269-6276.	3.2	32
50	Prevalence and predictors of probable depression in prostate cancer survivors. Cancer, 2019, 125, 3418-3427.	2.0	32
51	Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP. Annals of Epidemiology, 2019, 29, 16-22.e1.	0.9	32
52	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	0.9	32
53	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	0.9	32
54	Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis. Urology, 2016, 97, 124-129.	0.5	30

#	Article	IF	Citations
55	Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry, 1999, 35, 2-10.	1.8	29
56	Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5Î±-reductase inhibitors. Prostate, 2013, 73, 1470-1482.	1.2	29
57	The essential role of methylthioadenosine phosphorylase in prostate cancer. Oncotarget, 2016, 7, 14380-14393.	0.8	29
58	Biology of Castration-Recurrent Prostate Cancer. Urologic Clinics of North America, 2012, 39, 435-452.	0.8	28
59	5â€Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. Journal of Pathology, 2022, 256, 427-441.	2.1	28
60	A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemporary Clinical Trials, 2014, 38, 198-203.	0.8	27
61	Atmospheric Pressure Photoionization Tandem Mass Spectrometry of Androgens in Prostate Cancer. Analytical Chemistry, 2010, 82, 6000-6007.	3.2	26
62	Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway. Journal of Proteome Research, 2018, 17, 2963-2977.	1.8	26
63	Receipt of National Comprehensive Cancer Network guidelineâ€concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer, 2013, 119, 2282-2290.	2.0	25
64	Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4). Organic and Biomolecular Chemistry, 2017, 15, 7623-7629.	1.5	24
65	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	2.3	24
66	Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate, 2003, 57, 24-31.	1.2	23
67	Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment. International Journal of Biological Sciences, 2014, 10, 596-601.	2.6	23
68	Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. Nutrition and Cancer, 2016, 68, 214-224.	0.9	23
69	Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. PLoS ONE, 2015, 10, e0125151.	1.1	22
70	Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer. Cancer Research, 2019, 79, 1353-1368.	0.4	22
71	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	0.9	22
72	Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer. Translational Oncology, 2008, 1, 153-157.	1.7	21

#	Article	IF	Citations
73	Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate, 2014, 74, 722-731.	1.2	21
74	Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1395-1401.	2.3	21
75	The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biology and Therapy, 2010, 9, 1033-1042.	1.5	20
76	Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. British Journal of Nutrition, 2016, 115, 68-74.	1.2	20
77	Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	1.4	20
78	The Thoc1 Ribonucleoprotein and Prostate Cancer Progression. Journal of the National Cancer Institute, 2014, 106, dju306-dju306.	3.0	19
79	Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate, 2016, 76, 1053-1066.	1.2	19
80	Antineoplastic Isoflavonoids Derived from Intermediate orthoâ€Quinone Methides Generated from Mannich Bases. ChemMedChem, 2016, 11, 600-611.	1.6	19
81	Association among plasma 1,25(OH) 2 D, ratio of 1,25(OH) 2 D to 25(OH)D, and prostate cancer aggressiveness. Prostate, 2019, 79, 1117-1124.	1.2	19
82	Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer, 1994, 74, 2996-3001.	2.0	18
83	Phenotype-Specific CpG Island Methylation Events in a Murine Model of Prostate Cancer. Cancer Research, 2008, 68, 4173-4182.	0.4	18
84	Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents. Organic and Biomolecular Chemistry, 2015, 13, 11292-11301.	1.5	18
85	The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy. Current Drug Targets, 2013, 14, 420-440.	1.0	18
86	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolinaâ€“Louisiana Prostate Cancer Project. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 670-677.	1.1	17
87	Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World Journal of Urology, 1997, 15, 364-368.	1.2	16
88	New Developments in the Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 653-657.	2.3	16
89	Concept and viability of androgen annihilation for advanced prostate cancer. Cancer, 2014, 120, 2628-2637.	2.0	16
90	Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robotâ€assisted radical cystectomy for bladder cancer. BJU International, 2017, 119, 879-884.	1.3	16

#	Article	IF	Citations
91	Modelling attrition and nonparticipation in a longitudinal study of prostate cancer. BMC Medical Research Methodology, 2018, 18, 60.	1.4	16
92	Low Detectable Prostate Specific Antigen after Radical Prostatectomyâ€"Treat or Watch?. Journal of Urology, 2014, 192, 1390-1396.	0.2	15
93	Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer. Prostate, 2016, 76, 715-721.	1.2	14
94	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer and Prostatic Diseases, 2019, 22, 309-316.	2.0	14
95	A four gene signature predictive of recurrent prostate cancer. Oncotarget, 2017, 8, 3430-3440.	0.8	14
96	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical Cancer Research, 2022, 28, 414-424.	3.2	14
97	Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. BioMedical Engineering OnLine, 2005, 4, 31.	1.3	13
98	Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate, 2007, 67, 1011-1018.	1.2	13
99	14-3-3Î· Amplifies Androgen Receptor Actions in Prostate Cancer. Clinical Cancer Research, 2009, 15, 7571-7581.	3.2	13
100	The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate, 2013, 73, 1483-1494.	1.2	13
101	Efficient synthesis of aurone Mannich bases and evaluation of their antineoplastic activity in PC-3 prostate cancer cells. Chemical Papers, 2018, 72, 2443-2456.	1.0	13
102	Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU International, 2018, 121, 534-539.	1.3	13
103	Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate, 2015, 75, 1419-1435.	1.2	12
104	The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaPâ€NC. Prostate, 2017, 77, 878-887.	1.2	12
105	Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status. Biomolecules, 2020, 10, 1393.	1.8	12
106	Patterns and predictors of selfâ€reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 2019, 8, 3648-3658.	1.3	11
107	A CD24â€p53 axis contributes to African American prostate cancer disparities. Prostate, 2020, 80, 609-618.	1.2	11
108	Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget, 2018, 9, 11227-11242.	0.8	11

#	Article	IF	Citations
109	The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2016, 27, 1475-1485.	0.8	10
110	Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a longâ€term followâ€up study. Prostate, 2022, , .	1.2	10
111	Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram. Cancers, 2022, 14, 1644.	1.7	10
112	Comparison of ACINUS, caspaseâ€3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis. Prostate, 2009, 69, 1603-1610.	1.2	9
113	Mechanism of androgen receptor corepression by CKÎ²BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Molecular and Cellular Endocrinology, 2014, 382, 302-313.	1.6	9
114	Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line. Prostate, 2016, 76, 1067-1077.	1.2	9
115	Potential impact of combined inhibition of 3Î±-oxidoreductases and 5Î±-reductases on prostate cancer. Asian Journal of Urology, 2019, 6, 50-56.	0.5	9
116	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	2.0	9
117	Use of Abiraterone for Prostate Cancer. Journal of Urology, 2011, 185, 783-786.	0.2	8
118	Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. Prostate Cancer, 2015, 2015, 1-8.	0.4	8
119	Serumâ€free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate, 2018, 78, 213-221.	1.2	8
120	Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2018, 32, 730-736.	1.1	8
121	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	2.6	8
122	The Role of Motility Proteins and Metastasisâ€Suppressor Genes in Prostate Cancer Progression. Stem Cells, 1996, 14, 508-516.	1.4	7
123	Characterization of Prostate Cancer in a Functional Eunuch. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1054-1060.	2.3	7
124	Statin use, high cholesterol and prostate cancer progression; results from HCaPâ€NC. Prostate, 2018, 78, 857-864.	1.2	7
125	Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. , 2004, 26, 194-200.		7
126	Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5â€alpha reductase inhibitor treated human benign prostate hyperplasia patients. Prostate, 2022, 82, 1378-1388.	1.2	7

#	Article	IF	Citations
127	A novel method for the analysis of the androgen receptor. Current Urology Reports, 2002, 3, 67-74.	1.0	6
128	Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer. PLoS ONE, 2012, 7, e30192.	1.1	6
129	Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate, 2017, 77, 1076-1081.	1.2	6
130	Understanding the Relationship between Environmental Arsenic and Prostate Cancer Aggressiveness among African-American and European-American Men in North Carolina. International Journal of Environmental Research and Public Health, 2020, 17, 8364.	1.2	6
131	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Prostate, 2021, 81, 223-230.	1.2	6
132	Prostate tumorâ€“derived GDF11 accelerates androgen deprivation therapyâ€“induced sarcopenia. JCI Insight, 2020, 5, .	2.3	6
133	Tobacco use and outcome in radical prostatectomy patients. Cancer Medicine, 2017, 6, 857-864.	1.3	5
134	A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer. American Journal of Clinical and Experimental Urology, 2018, 6, 101-106.	0.4	5
135	Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. Canadian Journal of Urology, 2019, 26, 34-37.	0.0	5
136	Flow cytometric assay of pinocytosis: Correlation with membrane ruffling and metastatic potential in the dunning R-3327 rat prostatic adenocarcinoma model. Cytometry, 1993, 14, 826-831.	1.8	4
137	Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue. Prostate, 2015, 75, 1910-1915.	1.2	4
138	Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 663-665.	2.3	4
139	A Direct Synthesis of 2â€(ï‰â€Carboxyalkyl)isoflavones from orthoâ€Hydroxylated Deoxybenzoins. European Journal of Organic Chemistry, 2018, 2018, 5460-5463.	1.2	4
140	Pictetâ€“Spengler condensations using 4-(2-aminoethyl)coumarins. New Journal of Chemistry, 2020, 44, 13415-13429.	1.4	4
141	Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 990-999.	1.1	4
142	Unit Nonresponse in a Population-Based Study of Prostate Cancer. PLoS ONE, 2016, 11, e0168364.	1.1	4
143	Editorial: Treatment Issues in Clinically Localized Prostatic Carcinoma. Journal of Urology, 1995, 154, 1433-1434.	0.2	3
144	Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 1061-1068.	0.2	3

#	Article	IF	Citations
145	The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2018, 29, 1143-1150.	0.8	3
146	Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 597.	0.9	2
147	Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate, 2018, 78, 1069-1076.	1.2	2
148	Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer. , 2009, , 553-568.		2
149	INTRACRINE SYNTHESIS OF ANDROGENS BY PROSTATE CANCER IN RESPONSE TO ANDROGEN DEPRIVATION THERAPY. , 2011, , 193-218.		2
150	Ten Years of Progress in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 136-140.	2.3	1
151	5Î±-Reductase Isozymes in Castration-Recurrent Prostate Cancer. , 2009, , 175-185.		1
152	Racial Differences in Prostate Cancer Mortality. , 2007, , 355-376.		1
153	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. American Journal of Clinical and Experimental Urology, 2014, 2, 121-6.	0.4	1
154	Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer Causes and Control, 2022, , .	0.8	1
155	Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Menâ€™s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). European Urology Focus, 2022, 8, 1607-1616.	1.6	1
156	Genetic instability assessed by sister chromatid exchange analysis in the dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential. Prostate, 1995, 26, 247-252.	1.2	0
157	IL-15 The androgen axis in recurrent prostate cancer. Japanese Journal of Urology, 2004, 95, 280.	0.0	0
158	Editorial Comment. Journal of Urology, 2010, 183, 1797-1797.	0.2	0
159	In honor of Dr. Donald S. Coffey â€“ Prostate cancer biology and therapy. Asian Journal of Urology, 2019, 6, 1-2.	0.5	0
160	Whole grain and dietary fiber intake and prostate cancer aggressiveness by race. FASEB Journal, 2010, 24, 729.2.	0.2	0
161	Title is missing!. Japanese Journal of Urology, 2011, 102, 341.	0.0	0
162	Living WCRF Recommendations associated with less Prostate Cancer Aggressiveness among African and Caucasian Americans. FASEB Journal, 2012, 26, 388.4.	0.2	0